Flavin containing monooxygenase 3 exerts broad effects on glucose and lipid metabolism and atherosclerosis
Open accessThe DOI matches its Crossref record; 46 of the 46 references it cites were found in a registry or an index.
Abstract
We performed silencing and overexpression studies of flavin containing monooxygenase (FMO) 3 in hyperlipidemic mouse models to examine its effects on trimethylamine N-oxide (TMAO) levels and atherosclerosis. Knockdown of hepatic FMO3 in LDL receptor knockout mice using an antisense oligonucleotide resulted in decreased circulating TMAO levels and atherosclerosis. Surprisingly, we also observed significant decreases in hepatic lipids and in levels of plasma lipids, ketone bodies, glucose, and insulin. FMO3 overexpression in transgenic mice, on the other hand, increased hepatic and plasma lipids. Global gene expression analyses suggested that these effects of FMO3 on lipogenesis and gluconeogenesis may be mediated through the PPARα and Kruppel-like factor 15 pathways. In vivo and in vitro results were consistent with the concept that the effects were mediated directly by FMO3 rather than trimethylamine/TMAO; in particular, overexpression of FMO3 in the human hepatoma cell line, Hep3B, resulted in significantly increased glucose secretion and lipogenesis. Our results indicate a major role for FMO3 in modulating glucose and lipid homeostasis in vivo, and they suggest that pharmacologic inhibition of FMO3 to reduce TMAO levels would be confounded by metabolic interactions.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures









Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Nevertheless, there could be several problems with this approach as an accumulation of TMA leads to trimethylaminuria, which is characterized by fishy odor (similar to rotten fish) and induce inflammation [18,75,99].”
From Implication of Trimethylamine N-Oxide (TMAO) in Disease: Potential Biomarker or New Therapeutic Target (2018) · cites this paper as [99]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“important regulators in host lipid and sterol metabolism, as well as atherosclerosis development”
From Non-lethal Inhibition of Gut Microbial Trimethylamine Production for the Treatment of Atherosclerosis (2015) · cites this paper as Shih et al., 2015
In the citing paper
“FMO3 inhibition is also accompanied by several untoward side effects, including hepatic inflammation”
From Non-lethal Inhibition of Gut Microbial Trimethylamine Production for the Treatment of Atherosclerosis (2015) · cites this paper as Shih et al., 2015
In the citing paper
“host hepatic FMO3, the primary FMO responsible for TMAO production”
From Non-lethal Inhibition of Gut Microbial Trimethylamine Production for the Treatment of Atherosclerosis (2015) · cites this paper as Shih et al., 2015
In the citing paper
“suppression of the host enzyme, FMO3, through antisense oligonucleotide-based approach, results in reduction of both circulating TMAO levels and diet-enhanced atherosclerosis in animal models”
From Non-lethal Inhibition of Gut Microbial Trimethylamine Production for the Treatment of Atherosclerosis (2015) · cites this paper as Shih et al., 2015
6 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A SIMPLE METHOD FOR THE ISOLATION AND PURIFICATION OF TOTAL LIPIDES FROM ANIMAL TISSUES
Folch, J., Lees, M., & Stanley, G. H. S. (1957) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)64849-5 · Cited by 65,189
Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease
Wang, Z., Klipfell, E., Bennett, B. J., Koeth, R., Levison, B. S., DuGar, B., Feldstein, A. E., Britt, E. B., Fu, X., Chung, Y.-M., et al. (2011) · Nature · doi:10.1038/nature09922 · Cited by 5,597
Self-citationInsulin signalling and the regulation of glucose and lipid metabolism
Saltiel, A. R., & Kahn, C. R. (2001) · Nature · doi:10.1038/414799a · Cited by 5,326
Intestinal microbiota metabolism of l-carnitine, a nutrient in red meat, promotes atherosclerosis
Koeth, R. A., Wang, Z., Levison, B. S., Buffa, J. A., Org, E., Sheehy, B. T., Britt, E. B., Fu, X., Wu, Y., Li, L., et al. (2013) · Nature Medicine · doi:10.1038/nm.3145 · Cited by 4,386
Self-citationIntestinal microbial metabolism of phosphatidylcholine and cardiovascular risk
Tang, W. H. W., Wang, Z., Levison, B. S., Koeth, R. A., Britt, E. B., Fu, X., Wu, Y., & Hazen, S. L. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1109400 · Cited by 3,400
Self-citationRepa, J. J., Liang, G., Ou, J., Bashmakov, Y., Lobaccaro, J.-M. A., Shimomura, I., Shan, B., Brown, M. S., Goldstein, J. L., & Mangelsdorf, D. J. (2000) · Genes & Development · doi:10.1101/gad.844900 · Cited by 1,692
SREBP activity is regulated by mTORC1 and contributes to Akt-dependent cell growth
Porstmann, T., Santos, C. R., Griffiths, B., Cully, M., Wu, M., Leevers, S., Griffiths, J. R., Chung, Y.-L., & Schulze, A. (2008) · Cell Metabolism · doi:10.1016/j.cmet.2008.07.007 · Cited by 1,413
Delerive, P., De Bosscher, K., Besnard, S., Vanden Berghe, W., Peters, J. M., Gonzalez, F. J., Fruchart, J.-C., Tedgui, A., Haegeman, G., & Staels, B. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.45.32048 · Cited by 1,089
Bennett, B. J., Vallim, T. Q. D. A., Wang, Z., Shih, D. M., Meng, Y., Gregory, J., Allayee, H., Lee, R., Graham, M., Crooke, R., et al. (2013) · Cell Metabolism · doi:10.1016/j.cmet.2012.12.011 · Cited by 1,070
Self-citationLi, S., Brown, M. S., & Goldstein, J. L. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0914798107 · Cited by 733
Cited by
Gut Microbial Metabolite TMAO Enhances Platelet Hyperreactivity and Thrombosis Risk
Zhu, W., Gregory, J. C., Org, E., Buffa, J. A., Gupta, N., Wang, Z., Li, L., Fu, X., Wu, Y., Mehrabian, M., et al. (2016) · Cell · doi:10.1016/j.cell.2016.02.011 · Cited by 1,968
“, 2013), further confirm the involvement of this metaorganismal pathway in both atherosclerosis development and regulation of whole body cholesterol and sterol metabolism (Miao et al., 2015; Shih et al., 2015; Warrier et al., 2015).”
InfluentialSelf-citationGut microbiota in cardiovascular health and disease
Tang, W. H. W., Kitai, T., & Hazen, S. L. (2017) · Circulation Research · doi:10.1161/circresaha.117.309715 · Cited by 1,670
Self-citationWang, Z., Roberts, A. B., Buffa, J. A., Levison, B. S., Zhu, W., Org, E., Gu, X., Huang, Y., Zamanian-Daryoush, M., Culley, M. K., et al. (2015) · Cell · doi:10.1016/j.cell.2015.11.055 · Cited by 1,317
“…importance of both TMAO and host hepatic FMO3, the primary FMO responsible for TMAO production, as important regulators in host lipid and sterol metabolism, as well as atherosclerosis development (Bennett et al., 2013; Koeth et al., 2013; Shih et al., 2015; Wang et al., 2011; Warrier et al., 2015).”
BackgroundSelf-citationDietary lipids, gut microbiota and lipid metabolism
Schoeler, M., & Caesar, R. (2019) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-019-09512-0 · Cited by 1,163
Romano, K. A., Vivas, E. I., Amador-Noguez, D., & Rey, F. E. (2015) · mBio · doi:10.1128/mbio.02481-14 · Cited by 777
“Once TMA is absorbed by the host, it is further metabolized by flavin monooxygenases 1 and 3 (FMO1 and FMO3) in the host liver to generate trimethylamine-N-oxide (TMAO) (8, 15, 16).”
BackgroundRole of gut microbiota in atherosclerosis
Jonsson, A. L., & Bäckhed, F. (2017) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2016.183 · Cited by 644
Janeiro, M., Ramírez, M., Milagro, F., Martínez, J., & Solas, M. (2018) · Nutrients · doi:10.3390/nu10101398 · Cited by 631
Schiattarella, G. G., Sannino, A., Toscano, E., Giugliano, G., Gargiulo, G., Franzone, A., Trimarco, B., Esposito, G., & Perrino, C. (2017) · European Heart Journal · doi:10.1093/eurheartj/ehx342 · Cited by 563
Trimethylamine N-oxide: the good, the bad and the unknown.
Velasquez, M., Ramezani, A., Manal, A., & Raj, D. (2016) · Toxins · doi:10.3390/toxins8110326 · Cited by 504
“FMO3 enzyme inhibition [57] Prevented the oxidization of TMA to TMAO It has other effects on the regulation of both lipid metabolism and inflammation”
BackgroundMethodWang, Z., Bergeron, N., Levison, B. S., Li, X. S., Chiu, S., Jia, X., Koeth, R. A., Li, L., Wu, Y., Tang, W. H. W., et al. (2019) · European Heart Journal · doi:10.1093/eurheartj/ehy799 · Cited by 496
Self-citationLi, X. S., Obeid, S., Klingenberg, R., Gencer, B., Mach, F., Räber, L., Windecker, S., Rodondi, N., Nanchen, D., Muller, O., et al. (2017) · European Heart Journal · doi:10.1093/eurheartj/ehw582 · Cited by 479
Self-citationTrimethylamine N -Oxide, the Microbiome, and Heart and Kidney Disease
Zeisel, S. H., & Warrier, M. (2017) · Annual Review of Nutrition · doi:10.1146/annurev-nutr-071816-064732 · Cited by 475
“of TMA, leading to a fishy odor and inflammation as observed in antisense oligonucleotide-treated mice (102, 121).”
BackgroundResultGut microbiota derived metabolites in cardiovascular health and disease
Wang, Z., & Zhao, Y. (2018) · Protein & Cell · doi:10.1007/s13238-018-0549-0 · Cited by 471
Self-citationTrimethylamine N-Oxide Binds and Activates PERK to Promote Metabolic Dysfunction
Chen, S., Henderson, A., Petriello, M. C., Romano, K. A., Gearing, M., Miao, J., Schell, M., Sandoval-Espinola, W. J., Tao, J., Sha, B., et al. (2019) · Cell Metabolism · doi:10.1016/j.cmet.2019.08.021 · Cited by 427
Self-citationOrgan, C. L., Otsuka, H., Bhushan, S., Wang, Z., Bradley, J., Trivedi, R., Polhemus, D. J., Tang, W. H. W., Wu, Y., Hazen, S. L., et al. (2016) · Circulation: Heart Failure · doi:10.1161/circheartfailure.115.002314 · Cited by 382
“mouse model.(8) Numerous mechanistic investigations demonstrate a central role for the choline→TMAO metaorganismal pathway in cholesterol and sterol metabolism, macrophage phenotype, and reverse cholesterol transport.”
BackgroundSelf-citationFlavin-containing monooxygenase 3 as a potential player in diabetes-associated atherosclerosis
Miao, J., Ling, A. V., Manthena, P. V., Gearing, M. E., Graham, M. J., Crooke, R. M., Croce, K. J., Esquejo, R. M., Clish, C. B., Morbid Obesity Study Group, et al. (2015) · Nature Communications · doi:10.1038/ncomms7498 · Cited by 368
Self-citationFennema, D., Phillips, I. R., & Shephard, E. A. (2016) · Drug Metabolism and Disposition · doi:10.1124/dmd.116.070615 · Cited by 355
“Knockdown of FMO3 mRNA by antisense oligonucleotides in female low-density lipoprotein receptor-knockout mice suggests a role for FMO3 in modulating glucose and lipid homeostasis (Shih et al., 2015).”
BackgroundYang, S., Li, X., Yang, F., Zhao, R., Pan, X., Liang, J., Tian, L., Li, X., Liu, L., Xing, Y., et al. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.01360 · Cited by 345
l-Carnitine in omnivorous diets induces an atherogenic gut microbial pathway in humans
Koeth, R. A., Lam-Galvez, B. R., Kirsop, J., Wang, Z., Levison, B. S., Gu, X., Copeland, M. F., Bartlett, D., Cody, D. B., Dai, H. J., et al. (2018) · Journal of Clinical Investigation · doi:10.1172/jci94601 · Cited by 327
“Importantly, recent studies aimed at blocking the metaorganismal TMAO pathway through multiple approaches have confirmed the inhibition of diet-dependent atherosclerosis in animal models, either by targeting the initial microbial formation of TMA from choline through use of a nonlethal small-molecule inhibitor (19), o…”
Self-citationHaghikia, A., Li, X. S., Liman, T. G., Bledau, N., Schmidt, D., Zimmermann, F., Kränkel, N., Widera, C., Sonnenschein, K., Haghikia, A., et al. (2018) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.118.311023 · Cited by 311
Self-citationTrimethylamine-N-Oxide Instigates NLRP3 Inflammasome Activation and Endothelial Dysfunction
Boini, K. M., Hussain, T., Li, P.-L., & Koka, S. S. (2017) · Cellular Physiology and Biochemistry · doi:10.1159/000484623 · Cited by 302
Relationship of Serum Trimethylamine N-Oxide (TMAO) Levels with early Atherosclerosis in Humans
Randrianarisoa, E., Lehn-Stefan, A., Wang, X., Hoene, M., Peter, A., Heinzmann, S. S., Zhao, X., Königsrainer, I., Königsrainer, A., Balletshofer, B., et al. (2016) · Scientific Reports · doi:10.1038/srep26745 · Cited by 296
Schugar, R. C., Shih, D. M., Warrier, M., Helsley, R. N., Burrows, A., Ferguson, D., Brown, A. L., Gromovsky, A. D., Heine, M., Chatterjee, A., et al. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.05.077 · Cited by 291
“Immunoblotting experiments were performed as previously described (Shih et al., 2015).”
InfluentialSelf-citationSenthong, V., Wang, Z., Li, X. S., Fan, Y., Wu, Y., Wilson Tang, W. H., & Hazen, S. L. (2016) · Journal of the American Heart Association · doi:10.1161/jaha.115.002816 · Cited by 270
“Mueller and colleagues, for example, observed in a cohort of 339 patients undergoing angiographic evaluation that TMAO levels were confounded by impaired kidney function and poor metabolic control and were not associated with history, presence, or incidence of symptoms or events of CAD.32 Interestingly, levels reporte…”
BackgroundInfluentialSelf-citationTrimethylamine-N-oxide (TMAO)-induced atherosclerosis is associated with bile acid metabolism
Ding, L., Chang, M., Guo, Y., Zhang, L., Xue, C., Yanagita, T., Zhang, T., & Wang, Y. (2018) · Lipids in Health and Disease · doi:10.1186/s12944-018-0939-6 · Cited by 250
“The decreased insulin levels in the livers of FMO3 mice might result in reduced lipogenesis and further down-regulated PPARα expression [20].”
BackgroundTang, W. H. W., Wang, Z., Li, X. S., Fan, Y., Li, D. S., Wu, Y., & Hazen, S. L. (2017) · Clinical Chemistry · doi:10.1373/clinchem.2016.263640 · Cited by 231
“Moreover, manipulation of TMAO concentrations in mice through inhibition in host flavin monooxygenase 3 (FMO3), the key host enzyme responsible for converting TMA into TMAO (12), demonstrates the pathway exerts broad effects on glucose metabolism (12, 36).”
BackgroundSelf-citationJi, Y., Yin, Y., Li, Z., & Zhang, W. (2019) · Nutrients · doi:10.3390/nu11081712 · Cited by 230
Liu, Y., & Dai, M. (2020) · Mediators of Inflammation · doi:10.1155/2020/4634172 · Cited by 224
Duttaroy, A. K. (2021) · Nutrients · doi:10.3390/nu13010144 · Cited by 223
The Role of Gut Microbiota in Atherosclerosis and Hypertension
Ma, J., & Li, H. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.01082 · Cited by 224
Altered Gut Microbiota in Type 2 Diabetes: Just a Coincidence?
Sircana, A., Framarin, L., Leone, N., Berrutti, M., Castellino, F., Parente, R., De Michieli, F., Paschetta, E., & Musso, G. (2018) · Current Diabetes Reports · doi:10.1007/s11892-018-1057-6 · Cited by 223
Trimethylamine- N -Oxide: Friend, Foe, or Simply Caught in the Cross-Fire?
Cho, C. E., & Caudill, M. A. (2017) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2016.10.005 · Cited by 218
“FMO3 Activity and/or Genotype Although FMO3 activity is well recognized for its catalysis of TMA to TMAO [58], it also functions to regulate aspects of cholesterol metabolism and insulin sensitivity [59,60].”
BackgroundAssociation between microbiota-dependent metabolite trimethylamine-N-oxide and type 2 diabetes
Shan, Z., Sun, T., Huang, H., Chen, S., Chen, L., Luo, C., Yang, W., Yang, X., Yao, P., Cheng, J., et al. (2017) · The American Journal of Clinical Nutrition · doi:10.3945/ajcn.117.157107 · Cited by 210
Role of gut microbiota in cardiovascular diseases
Novakovic, M., Rout, A., Kingsley, T., Kirchoff, R., Singh, A., Verma, V., Kant, R., & Chaudhary, R. (2020) · World Journal of Cardiology · doi:10.4330/wjc.v12.i4.110 · Cited by 202
Gut Microbiota-Derived TMAO: A Causal Factor Promoting Atherosclerotic Cardiovascular Disease?
Canyelles, M., Borràs, C., Rotllan, N., Tondo, M., Escolà-Gil, J. C., & Blanco-Vaca, F. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24031940 · Cited by 194
“levels, the bile acid pool size, and glucose and insulin levels and prevented atherosclerosis in LDL receptor-deficient mice [65], suggesting multiple mechanistic processes involved in TMAO/FMO3-mediated foam cell formation in vivo.”
Rohrmann, S., Linseisen, J., Allenspach, M., von Eckardstein, A., & Müller, D. (2016) · The Journal of Nutrition · doi:10.3945/jn.115.220103 · Cited by 197
Arias, N., Arboleya, S., Allison, J., Kaliszewska, A., Higarza, S. G., Gueimonde, M., & Arias, J. L. (2020) · Nutrients · doi:10.3390/nu12082340 · Cited by 196
Skye, S. M., Zhu, W., Romano, K. A., Guo, C.-J., Wang, Z., Jia, X., Kirsop, J., Haag, B., Lang, J. M., DiDonato, J. A., et al. (2018) · Circulation Research · doi:10.1161/circresaha.118.313142 · Cited by 189
Self-citationCanyelles, M., Tondo, M., Cedó, L., Farràs, M., Escolà-Gil, J. C., & Blanco-Vaca, F. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19103228 · Cited by 188
The gut microbiota as a novel regulator of cardiovascular function and disease
Battson, M. L., Lee, D. M., Weir, T. L., & Gentile, C. L. (2018) · The Journal of Nutritional Biochemistry · doi:10.1016/j.jnutbio.2017.12.010 · Cited by 183
Li, D., Lu, Y., Yuan, S., Cai, X., He, Y., Chen, J., Wu, Q., He, D., Fang, A., Bo, Y., et al. (2022) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/nqac074 · Cited by 178
“…by blocking the hepatic insulin signaling pathway and causing inflammation in adipose tissue (131), whereas a decrease of plasma TMAO could reduce plasma glucose and insulin resistance in mice by inhibiting the main TMAO-generating enzyme FMO3 (flavin-containing monooxygenase-3) (132).”
Gut microbiome, endocrine control of gut barrier function and metabolic diseases
Régnier, M., Van Hul, M., Knauf, C., & Cani, P. D. (2021) · Journal of Endocrinology · doi:10.1530/joe-20-0473 · Cited by 179
Heianza, Y., Sun, D., Li, X., DiDonato, J. A., Bray, G. A., Sacks, F. M., & Qi, L. (2019) · Gut · doi:10.1136/gutjnl-2018-316155 · Cited by 177
Gut Microbiota and Ischemic Stroke: The Role of Trimethylamine N-Oxide
Nam, H. S. (2019) · Journal of Stroke · doi:10.5853/jos.2019.00472 · Cited by 176
“FMO3 plays an important role in the regulation of blood glucose and cholesterol levels in addition to bile acid metabolism.(11) Fish odor syndrome (trimethylaminuria) is a genetic disease associated with mutations in the FMO3 gene.”
BackgroundTrimethylamine N ‐Oxide and Mortality Risk in Patients With Peripheral Artery Disease
Senthong, V., Wang, Z., Fan, Y., Wu, Y., Hazen, S. L., & Tang, W. H. W. (2016) · Journal of the American Heart Association · doi:10.1161/jaha.116.004237 · Cited by 175
“In several recent studies genetically repressing hepatic flavin monooxygenase 3 expression, the host enzyme primarily responsible for converting gut microbe–generated TMA into TMAO, choline diet–enhanced atherosclerosis was inhibited, further implicating the TMAO pathway in atherosclerosis development.(18,19) These an…”
BackgroundSelf-citationInteraction between gut microbiome and cardiovascular disease
Peng, J., Xiao, X., Hu, M., & Zhang, X. (2018) · Life Sciences · doi:10.1016/j.lfs.2018.10.063 · Cited by 174
Expanding role of gut microbiota in lipid metabolism
Ghazalpour, A., Cespedes, I., Bennett, B. J., & Allayee, H. (2016) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000278 · Cited by 172
Self-citationThe role of the gut microbiome in chronic liver disease: the clinical evidence revised
Schwenger, K. J., Clermont-Dejean, N., & Allard, J. P. (2019) · JHEP Reports · doi:10.1016/j.jhepr.2019.04.004 · Cited by 171
Microbiome, trimethylamine N-oxide, and cardiometabolic disease
Tang, W. H. W., & Hazen, S. L. (2017) · Translational Research · doi:10.1016/j.trsl.2016.07.007 · Cited by 160
Self-citationZhu, W., Buffa, J. A., Wang, Z., Warrier, M., Schugar, R., Shih, D. M., Gupta, N., Gregory, J. C., Org, E., Fu, X., et al. (2018) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.14234 · Cited by 161
Self-citationCell nonautonomous activation of flavin-containing monooxygenase promotes longevity and health span
Leiser, S. F., Miller, H., Rossner, R., Fletcher, M., Leonard, A., Primitivo, M., Rintala, N., Ramos, F. J., Miller, D. L., & Kaeberlein, M. (2015) · Science · doi:10.1126/science.aac9257 · Cited by 159
Inhibition of microbiota-dependent TMAO production attenuates chronic kidney disease in mice
Zhang, W., Miikeda, A., Zuckerman, J. E., Jia, X., Charugundla, S., Zhou, Z., Kaczor‐Urbanowicz, K. E., Magyar, C. E., Guo, F., Wang, Z., et al. (2021) · Scientific Reports · doi:10.1038/s41598-020-80063-0 · Cited by 158
Self-citationTrimethylamine N-Oxide in Relation to Cardiometabolic Health—Cause or Effect?
Papandreou, C., Moré, M., & Bellamine, A. (2020) · Nutrients · doi:10.3390/nu12051330 · Cited by 146
“Shih 2015 [29,118] Male hyperlipidemic mouse “E3L Tg” with transgenic FMO3 overexpression Transgenic compared to control mice; low-fat or high-fat/1% cholesterol chow for 16 weeks Increased plasma TG, VLDL/IDL/LDL, and unesterified cholesterol with both diets, increased glucose and insulin levels, increased levels of…”
BackgroundInfluentialUnravelling the involvement of gut microbiota in type 2 diabetes mellitus
Arora, A., Behl, T., Sehgal, A., Singh, S., Sharma, N., Bhatia, S., Sobarzo‐Sánchez, E., & BUNGAU, S. G. (2021) · Life Sciences · doi:10.1016/j.lfs.2021.119311 · Cited by 158
Organ, C. L., Li, Z., Sharp, T. E., Polhemus, D. J., Gupta, N., Goodchild, T. T., Tang, W. H. W., Hazen, S. L., & Lefer, D. J. (2020) · Journal of the American Heart Association · doi:10.1161/jaha.119.016223 · Cited by 135
Self-citationHartiala, J. A., Wilson Tang, W. H., Wang, Z., Crow, A. L., Stewart, A. F. R., Roberts, R., McPherson, R., Erdmann, J., Willenborg, C., Hazen, S. L., et al. (2016) · Nature Communications · doi:10.1038/ncomms10558 · Cited by 130
“Although the precise role of TMAO in physiological processes and atherogenesis is not entirely known, both it and FMO3 , the major enzyme responsible for generating TMAO 8 , have been linked to alterations in cholesterol and sterol metabolism 13,14 , as well as inflammatory gene expression 6,14 .”
Self-citationMan, A. W. C., Zhou, Y., Xia, N., & Li, H. (2020) · Nutrients · doi:10.3390/nu12103054 · Cited by 128
“Knocking down of host liver FMO3 in low density lipoprotein receptor (Ldlr)-deficient mice reduces the hepatic and plasma lipid levels, bile acid pool size, liver triglyceride secretion, ketone bodies, and glucose and insulin levels, resulting in the prevention of atherosclerosis [130].”
BackgroundModulating the Microbiota as a Therapeutic Intervention for Type 2 Diabetes
Huda, M. N., Kim, M., & Bennett, B. J. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.632335 · Cited by 142
Self-citationFerguson, J. F., Allayee, H., Gerszten, R. E., Ideraabdullah, F., Kris-Etherton, P. M., Ordovás, J. M., Rimm, E. B., Wang, T. J., & Bennett, B. J. (2016) · Circulation: Cardiovascular Genetics · doi:10.1161/hcg.0000000000000030 · Cited by 123
Self-citationThe role of the gut microbiota in health and cardiovascular diseases
Wang, L., Wang, S., Zhang, Q., He, C., Fu, C., & Wei, Q. (2022) · Molecular Biomedicine · doi:10.1186/s43556-022-00091-2 · Cited by 122
TMAO as a biomarker of cardiovascular events: a systematic review and meta-analysis
Guasti, L., Galliazzo, S., Molaro, M., Visconti, E., Pennella, B., Gaudio, G. V., Lupi, A., Grandi, A. M., & Squizzato, A. (2020) · Internal and Emergency Medicine · doi:10.1007/s11739-020-02470-5 · Cited by 141
“A third potential target could be FMO3: its inhibition might halt the necessary final step for TMAO production [33, 34].”
BackgroundGiuffrè, M., Campigotto, M., Campisciano, G., Comar, M., & Crocè, L. S. (2020) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00161.2019 · Cited by 126
Influence of gut microbiota on the development and progression of nonalcoholic steatohepatitis
Ghetti, F. D. F., de Oliveira, D. G., de Oliveira, J. M., Ferreira, L. E. V. V. D. C., Cesar, D. E., & Moreira, A. P. B. (2017) · European Journal of Nutrition · doi:10.1007/s00394-017-1524-x · Cited by 129
“These effects may be mediated through the peroxisome proliferator-activated receptor alpha (PPARα) and Kruppel-like factor 15 (KLF15) pathways [138].”
BackgroundTomlinson, J. A. P., & Wheeler, D. C. (2017) · Kidney International · doi:10.1016/j.kint.2017.03.053 · Cited by 126
Obeid, R., Awwad, H. M., Rabagny, Y., Graeber, S., Herrmann, W., & Geisel, J. (2016) · The American Journal of Clinical Nutrition · doi:10.3945/ajcn.115.121269 · Cited by 117
“Animal models of FMO3 and TMAO metabolism have shown variability, and the extrapolation of results obtained therein to humans requires care (1, 3, 6).”
BackgroundFoti, R., & Dalvie, D. (2016) · Drug Metabolism and Disposition · doi:10.1124/dmd.116.071753 · Cited by 120
Probiotic mechanisms of action
Halloran, K., & Underwood, M. A. (2019) · Early Human Development · doi:10.1016/j.earlhumdev.2019.05.010 · Cited by 117
Intra-individual variation of plasma trimethylamine-N-oxide (TMAO), betaine and choline over 1 year
Kühn, T., Rohrmann, S., Sookthai, D., Johnson, T., Katzke, V., Kaaks, R., von Eckardstein, A., & Müller, D. (2017) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm-2016-0374 · Cited by 110
“While correlations of TMAO with HbA1c, LDL, triglycerides and CRP may have been expected in consideration of experimental findings [3, 38], our results are consistent with those of previous epidemiological studies [33].”
ResultSavi, M., Bocchi, L., Bresciani, L., Falco, A., Quaini, F., Mena, P. R., Brighenti, F., Crozier, A., Stilli, D., & Rio, D. D. (2018) · Molecules · doi:10.3390/molecules23030549 · Cited by 114
“As recently reviewed by Velasquez and colleagues [12], efforts have been directed to verifying the effects of some main strategies for preventing TMAO damages to the human body, namely: (i) limiting the intake of phosphatidylcholine/choline and/or carnitine rich food [6]; (ii) targeting the microbiota composition to l…”
BackgroundTrimethylamine N-oxide levels are associated with NASH in obese subjects with type 2 diabetes
León‐Mimila, P., Villamil‐Ramírez, H., Li, X. S., Shih, D. M., Hui, S. T. Y., Ocampo‐Medina, E., López-Contreras, B. E., Morán‐Ramos, S., Olivares-Arévalo, M., Grandini-Rosales, P., et al. (2020) · Diabetes & Metabolism · doi:10.1016/j.diabet.2020.07.010 · Cited by 119
“Furthermore, these effects seem to be mediated by insulin and inflammatory signaling, bile acid metabolism and lipogenesis, resulting in the accumulation of fat in liver, hepatotoxicity and liver function impairment [20, 37, 38].”
BackgroundSelf-citationPraveenraj, S. S., Sonali, S., Anand, N., Hediyal, T. A., Vichitra, C., Kalyan, M., Kanna, P. V., Chandana, K. A., Paneyala, S., Mahalakshmi, A. M., et al. (2022) · Molecular Neurobiology · doi:10.1007/s12035-022-02990-5 · Cited by 121
“Additionally, besides bile acid metabolism, FMO3 plays a crucial function in blood glucose and cholesterol management [42].”
BackgroundBrown, J. M., & Hazen, S. L. (2017) · Journal of Biological Chemistry · doi:10.1074/jbc.r116.765388 · Cited by 108
“Interest in TMAO as a drug target is bolstered by a wealth of recent independent human studies, which have amply demonstrated that elevated circulating TMAO levels are associated with increased risk of CVD in a variety of cohorts (39,47-65).”
BackgroundSelf-citationBergeron, N., Williams, P. T., Lamendella, R., Faghihnia, N., Grube, A., Li, X., Wang, Z., Knight, R., Jansson, J. K., Hazen, S. L., et al. (2016) · British Journal of Nutrition · doi:10.1017/s0007114516004165 · Cited by 100
“Moreover, in two different mouse models of atherosclerosis, anti-sense oligonucleotide targeting of hepatic flavin monooxygenase 3 has been shown to similarly inhibit TMAO formation and development of atherosclerosis((34,35)).”
BackgroundSelf-citationMetabolites Linking the Gut Microbiome with Risk for Type 2 Diabetes
Zhu, T., & Goodarzi, M. O. (2020) · Current Nutrition Reports · doi:10.1007/s13668-020-00307-3 · Cited by 118
Diet-gut microbiota interactions on cardiovascular disease
Zhang, X., & Gérard, P. (2022) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2022.03.028 · Cited by 105
“TMA is further absorbed into blood stream and oxidized in the liver by flavin monooxygenases (FMOs, mainly FMO3) to generate TMAO [63,92].”
BackgroundFrom role of gut microbiota to microbial-based therapies in type 2-diabetes
Ebrahimzadeh Leylabadlo, H., Sanaie, S., Sadeghpour Heravi, F., Ahmadian, Z., & Ghotaslou, R. (2020) · Infection, Genetics and Evolution · doi:10.1016/j.meegid.2020.104268 · Cited by 92
Mosterd, C. M., Kanbay, M., van den Born, B. H., van Raalte, D. H., & Rampanelli, E. (2021) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2021.101484 · Cited by 104
Contribution of Trimethylamine N-Oxide (TMAO) to Chronic Inflammatory and Degenerative Diseases
Constantino-Jonapa, L. A., Espinoza-Palacios, Y., Escalona‐Montaño, A. R., Hernández-Ruiz, P., Amezcua-Guerra, L. M., Amedei, A., & Aguirre‐García, M. M. (2023) · Biomedicines · doi:10.3390/biomedicines11020431 · Cited by 102
“Contrarily, a high amount of FMO3 increased insulin resistance and the plasma concentration of glucose [85].”
Shanmugham, M., Bellanger, S., & Leo, C. H. (2023) · Pharmaceuticals · doi:10.3390/ph16040504 · Cited by 111
Busnelli, M., Manzini, S., & Chiesa, G. (2019) · Nutrients · doi:10.3390/nu12010079 · Cited by 98
Liu, J., Zhang, T., Wang, Y., Si, C., Wang, X., Wang, R.-T., & Lv, Z. (2020) · Aging · doi:10.18632/aging.102846 · Cited by 90
“Furthermore, suppression of FMO3 decreases circulating TMAO levels and reduces atherosclerosis [23].”
BackgroundTMAO as a potential biomarker and therapeutic target for chronic kidney disease: A review
Ye, Z., Lulu, C., Xiangchang, Z., Fang, Q., Binjie, Z., Chunyang, L., Rao, T., & Dongsheng, O. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.929262 · Cited by 104
“Antisense oligonucleotide knockout FMO3 inmice reduced atherosclerosis, and downregulation of FMO3 not only reduced TMAO level but also regulated lipid metabolism and inflammation, thereby reducing atherosclerosis (Shih et al., 2015).”
BackgroundPathak, P., Helsley, R. N., Brown, A. L., Buffa, J. A., Choucair, I., Nemet, I., Gogonea, C. B., Gogonea, V., Wang, Z., Garcia-Garcia, J. C., et al. (2020) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00584.2019 · Cited by 86
Self-citationOrg, E., Mehrabian, M., & Lusis, A. J. (2015) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2015.05.035 · Cited by 85
“Studies in mice have shown that inhibition of FMO3 reduced TMAO levels while over-expression increased TMAO levels [94,102].”
Self-citationCirculating Metabolites Originating from Gut Microbiota Control Endothelial Cell Function
Amedei, A., & Morbidelli, L. (2019) · Molecules · doi:10.3390/molecules24213992 · Cited by 89
Flavin-containing monooxygenases in aging and disease: Emerging roles for ancient enzymes
Rossner, R., Kaeberlein, M. R., & Leiser, S. F. (2017) · Journal of Biological Chemistry · doi:10.1074/jbc.r117.779678 · Cited by 93
“Several hormone receptors have been placed both upstream and downstream of FMOs (39, 40).”
BackgroundGao, J., Yan, K.-T., Wang, J.-X., Dou, J., Wang, J., Ren, M., Ma, J., Zhang, X., & Liu, Y. (2020) · Scientific Reports · doi:10.1038/s41598-020-59235-5 · Cited by 80
Plasma concentration of trimethylamine-N-oxide and risk of gestational diabetes mellitus
Li, P., Zhong, C., Li, S., Sun, T., Huang, H., Chen, X., Zhu, Y., Hu, X., Peng, X., Zhang, X., et al. (2018) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/nqy116 · Cited by 76
“Then, knockdown of FMO3 in insulin-resistant mice entirely normalized glucose tolerance and improved insulin tolerance through the suppression of forkhead box O1, a central node for metabolic control.”
BackgroundInfluentialTrimethylamine N -oxide: heart of the microbiota–CVD nexus?
Naghipour, S., Cox, A. J., Peart, J. N., Toit, E. F. D., & Headrick, J. P. (2020) · Nutrition Research Reviews · doi:10.1017/s0954422420000177 · Cited by 86
“Metabolic effects of FMO3 manipulation in LDL receptor knockout mice are TMA/TMAO independent(28,159).”
BackgroundFarhangi, M. A., Vajdi, M., & Asghari-Jafarabadi, M. (2020) · Nutrition Journal · doi:10.1186/s12937-020-00592-2 · Cited by 72
Relationship between elevated plasma trimethylamine N-oxide levels and increased stroke injury
Wu, C., Xue, F., Lian, Y., Zhang, J., Wu, D., Xie, N., Chang, W., Chen, F., Wang, L., Wei, W., et al. (2020) · Neurology · doi:10.1212/wnl.0000000000008862 · Cited by 76
Lemaître, R. N., Jensen, P. N., Wang, Z., Fretts, A. M., McKnight, B., Nemet, I., Biggs, M. L., Sotoodehnia, N., Otto, M. C. D. O., Psaty, B. M., et al. (2021) · JAMA Network Open · doi:10.1001/jamanetworkopen.2021.22844 · Cited by 74
Self-citationTrimethylamine-N-oxide: a link between the gut microbiome, bile acid metabolism, and atherosclerosis
Wilson, A., McLean, C., & Kim, R. B. (2016) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000274 · Cited by 71
Phillips, I. R., & Shephard, E. A. (2019) · Xenobiotica · doi:10.1080/00498254.2019.1643515 · Cited by 76
“Studies on mice have suggested a number of roles for FMO3 itself in health and disease, including modulation of glucose and lipid homeostasis (Shih et al., 2015), involvement in cholesterol metabolism and reverse cholesterol transport (Bennett et al., 2013; Warrier et al., 2015), and as a target…”
BackgroundGut microbiome and cardiovascular disease
Zhao, Y., & Wang, Z. (2020) · Current Opinion in Cardiology · doi:10.1097/hco.0000000000000720 · Cited by 77
Self-citationChen, P., Li, S., Koh, Y., Wu, J.-C., Yang, M., Ho, C., & Pan, M. (2019) · Journal of Agricultural and Food Chemistry · doi:10.1021/acs.jafc.9b03092 · Cited by 71
Self-citationTemel, R. E., & Brown, J. M. (2015) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2015.04.002 · Cited by 68
Self-citationShih, D. M., Zhu, W., Schugar, R. C., Meng, Y., Jia, X., Miikeda, A., Wang, Z., Zieger, M., Lee, R., Graham, M., et al. (2019) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.119.312592 · Cited by 67
“There are 2 likely mechanisms that can explain the differences observed between the genetic mutation of FMO3 and acute knockdown of FMO3 using an ASO: (1) the ASO used in our previous study may have off-target effects, or (2) there is genetic compensation induced in FMO3KO mice but not in FMO3 knockdown using an ASO.”
InfluentialSelf-citationIntestinal phospholipid and lysophospholipid metabolism in cardiometabolic disease
Hui, D. Y. (2016) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000334 · Cited by 67
Huo, X., Li, J., Cao, Y.-F., Li, S.-N., Shao, P., Leng, J., Li, W., Liu, J., Yang, K., Ma, R. C. W., et al. (2019) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2019-00710 · Cited by 65
Metadata
- Authors
- Shih, D. M., Wang, Z., Lee, R., Meng, Y., Che, N., Charugundla, S., Qi, H., Wu, J., Pan, C., Brown, J. M., Vallim, T., Bennett, B. J., Graham, M., Hazen, S. L., & Lusis, A. J.
- Affiliations
- University of California, Los Angeles (US)
- Cleveland Clinic (US)
- Ionis Pharmaceuticals (United States) (US)
- University of North Carolina at Chapel Hill (US)
- Corresponding author
- Lusis, Aldons J.
- ORCID
- Venue
- Journal of Lipid Research
- Publisher
- Elsevier BV
- Published
- 2015-01
- Volume
- 56
- Issue
- 1
- Pages
- 22-37
- ISSN
- 0022-2275 (ISSN-L)
- PMC
- PMC4274068
- OpenAlex
- W2163604084
- Cited by
- 335
- References
- 46
- Citations by year
- 2026: 17 · 2025: 19 · 2024: 18 · 2023: 20 · 2022: 43 · 2021: 36 · 2020: 44 · 2019: 33 · 2018: 28 · 2017: 28 · 2016: 33 · 2015: 16
- FWCI
- 29.47
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- creativecommons.org/licenses/by/4.0/ (vor, 2088 d)
- Locations
- Journal of Lipid Research (publishedVersion, cc-by)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Carolina Digital Repository (University of North Carolina at Chapel Hill) (submittedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- eScholarship (California Digital Library) (submittedVersion, cc-by)
- UNC Libraries
- Funders
- National Institutes of Health (HL‐28481, HL30568, HL113452)
- National Heart, Lung, and Blood Institute (HL3 0568, HL28481, P01HL030568, HL113452, P20HL113452, P01HL028481)
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Pharmacogenetics and Drug Metabolism
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Clinical Biochemistry › Paraoxonase enzyme and polymorphisms
- Keywords
- FMO3, trimethylamine N-oxide, atherosclerosis, glucose metabolism, lipid metabolism, hepatic lipogenesis, gluconeogenesis, PPARα, KLF15, hyperlipidemia, LDL receptor knockout mice, hepatic lipid accumulation, insulin, ketone bodies
- MeSH terms
- Animals, Bile Acids and Salts, DNA-Binding Proteins, Feces, Female, Glucose, Homeostasis, Humans, Insulin, Intestinal Mucosa, Lipoproteins, Liver, Methylamines, Oxygenases, Receptors, LDL, Transcription Factors, Gene Expression Regulation, Enzymologic, Cell Line, Tumor, PPAR alpha, Lipogenesis, Atherosclerosis, Lipid Metabolism, Mice, Kruppel-Like Transcription Factors, Gene Knockdown Techniques, Gene Knockout Techniques, Diet, Western
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.